AgingResearch.NewsJoin free

Mito-modulatory medication

Intervention

1 paper3 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 1 lab in 1 country
  • 1 finding against
  • Humans1

Outcomes

2

MAX ETS

no changein humans1downin humans1

1 study

  1. Mito-modulatory medication has no effect on MAX ETS in humans (p>0.05).

    “but not for women (p>0.05).”

    Humansskeletal musclefemales

    MITO-MODULATORY MEDICATION USE AND SKELETAL MUSCLE BIOENERGETICS IN OLDER ADULTS

    GSA 2024 abstract31 Dec 2024

  2. Mito-modulatory medication decreases MAX ETS in humans (mean 82.4 vs 92.7, p=0.0021).

    “MAX ETS was lower in mito-modulatory medication users (mean= 82.4 [77.7-87.0]) compared to non-users (mean= 92.7 [87.5-97.9]) for men (p=0.0021)”

    Humansskeletal musclemales

    MITO-MODULATORY MEDICATION USE AND SKELETAL MUSCLE BIOENERGETICS IN OLDER ADULTS

    GSA 2024 abstract31 Dec 2024

More on MAX ETS

ATPmax

downin humans1

1 study

  1. Mito-modulatory medication decreases ATPmax in humans (mean 0.54 vs 0.62, p=0.0004).

    “ATP-Max was lower in mito-modulatory medication users (mean= 0.54 [0.50-0.57]) compared to non-users (mean= 0.62 [0.58-0.66]) for men (p=0.0004).”

    Humansskeletal musclemales

    MITO-MODULATORY MEDICATION USE AND SKELETAL MUSCLE BIOENERGETICS IN OLDER ADULTS

    GSA 2024 abstract31 Dec 2024

More on ATPmax

Latest

Related